EN DE
Watch Damora Therapeutics, Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Damora Therapeutics, Inc. (DMRA) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Damora Therapeutics, Inc. stock $16.22, price $22.50, that is 27.9% below the price, quality 41 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN KYG2646Y1044

DT Damora Therapeutics, Inc. logo Thin data Nov 17, 2026

Damora Therapeutics, Inc.

DMRA · US

Expensive (fair value 28% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Quality 41/100 
Insiders bought $252,875 (6M) · sold $7,345 
Fair value $16.22 · Overvalued 
Falling price (downtrend) 
Negative free cash flow 
Trails peers (2/7) 
Narrow moat 5/100 · thin data
Thin data 
Estimate
Watch Damora Therapeutics, Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$112.50 $2.22 Fair Value $16.22 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.

How to read this chart

60‑month range $2.22 – $112.50 · fair‑value band $12.16 – $20.27 · the $22.50 price screens above the $16.22 fair value. As of Nov 17, 2026.

Follow Damora Therapeutics in your weekly email

Every Wednesday you see whether Damora Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America.

Show moreShow less

The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.

It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Stock analysis

Damora Therapeutics, Inc. (DMRA) currently trades at $22.50, while our estimate is $16.22, 28% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $12.16 (bear) to $20.27 (bull), the price of $22.50 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.

Damora Therapeutics, Inc. reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$210M in FY2025.

Key figures

Market cap $1.4B Small · P/E ratio 13.2 · EPS (TTM) $1.71 · Return on equity −116% · Return on assets (EBIT) −80.3% (5-year average) · Free cash flow −$6.7M · Net cash $258M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (low confidence).

What moves the price

The share trades about 34% below its 52-week high and 38% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −28%, DMRA screens richer than that median.

Fair Value

Bear $12.16 Fair Value $16.22 Bull $20.27
Price $22.50 · Downside -27.9%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 41/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 75
Are margins and returns getting better?
Cashflow 50
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 11
How calm the share price moves, does not count
Price momentum 13
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 23
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director bought shares worth $252,875, on Sep 25, 2026. Over the same period, one person sold shares worth $7,345.

  • BuyJennifer JarrettDirector, President and CEO, Director12,500 shares at $20.23$252,875Sep 25, 2026
  • SaleGarrett WinslowGeneral Counsel2× since Jan 2, 2026: 500 shares, avg. $25.59$12,797Jul 6, 2026
  • SaleLori FirmaniChief Financial Officer135 shares at $21.41$2,890Jan 2, 2026
  • SaleHans T. SchambyeChief Executive Officer, Director700 shares at $21.38$14,966Jan 2, 2026

Plus one other filing such as a grant, option exercise or tax withholding. It is not a market purchase or sale.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

DMRA screens overvalued: fair value 28% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Damora Therapeutics, Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks

Beats the industry median on 2/5 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 41 · Above median
Fair Value upside −27.9% · Below median
Profitability
Return on assets −80.5% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (12 months) 13.2× · Cheaper than median
P/B 6.00× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs DMRA
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs DMRA
Samsung Biologics Co 207940 1,423,000 KRW 1,552,100 KRW +9% vs DMRA
argenx SE ARGX $950.95 $908.40 −4% vs DMRA
CSL Limited CSL A$199.55 A$186.49 −7% vs DMRA
Moderna, Inc MRNA $215.27 $135.64 −37% vs DMRA
BeOne Medicines AG 6160 HK$249.40 HK$152.92 −39% vs DMRA
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs DMRA
Celltrion, Inc 068270 214,500 KRW 74,945 KRW −65% vs DMRA
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs DMRA

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Damora Therapeutics, Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Damora Therapeutics, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/DMRA

Frequently asked questions

Is Damora Therapeutics, Inc. (DMRA) overvalued or undervalued?
As of Nov 17, 2026, our estimate of fair value is $16.22 versus a price of $22.50, about 28% lower (overvalued).
What is the fair value of DMRA?
Our estimate for Damora Therapeutics, Inc. is $16.22 (as of Nov 17, 2026), built from audited fundamentals. The current price: $22.50.
What is the quality score of DMRA?
Damora Therapeutics, Inc. has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Damora Therapeutics, Inc. (DMRA)?
Our calculated price target is the estimate of $16.22 (as of Nov 17, 2026). Cautious scenario $12.16, optimistic scenario $20.27. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Damora Therapeutics, Inc. stock forecast for 2026?
Our estimate puts fair value at $16.22, about 28% lower versus a price of $22.50 (overvalued). Cautious scenario $12.16, optimistic scenario $20.27. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Damora Therapeutics, Inc. (DMRA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Damora Therapeutics, Inc. it is $16.22 per share (as of Nov 17, 2026), against a price of $22.50.
Is Damora Therapeutics, Inc. stock overvalued or undervalued in 2026?
As of Nov 17, 2026, DMRA trades above its calculated fair value: price $22.50, fair value $16.22, a gap of about −28% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DMRA?
No. The price is what the market pays today ($22.50); the fair value is what the company's own numbers justify ($16.22). For Damora Therapeutics, Inc. the two are $6.28 per share apart. That gap is exactly why we show both numbers side by side.
How much is Damora Therapeutics, Inc. worth?
The market values Damora Therapeutics, Inc. at about $1.4B (market capitalisation, as of Nov 17, 2026). Per share that is $22.50; our models calculate a fair value of $16.22 per share.
What do the bullish and bearish scenarios say about DMRA?
Our models span a range for Damora Therapeutics, Inc.: cautious scenario $12.16, base $16.22, optimistic $20.27 per share (as of Nov 17, 2026, price $22.50). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of DMRA?
Damora Therapeutics, Inc. trades at a price-to-earnings ratio of 13.2 (as of Nov 17, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $16.22 is built from several models across several years. Other multiples: P/B 6.0.
How solid is the balance sheet of Damora Therapeutics, Inc. (DMRA)?
Balance-sheet figures for Damora Therapeutics, Inc. (as of Nov 17, 2026): return on equity −115.8%. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is DMRA from its 52-week high?
Damora Therapeutics, Inc. trades at $22.50, about 34% below its 52-week high of $34.14 and 38% above the low of $16.31 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $16.22 is for.
Which stocks are comparable to Damora Therapeutics, Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Damora Therapeutics, Inc. stock attractive at the current price?
The data as of Nov 17, 2026: price $22.50, calculated fair value $16.22 (−28%), Quality Score 41/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Damora Therapeutics, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Damora Therapeutics, Inc. (DMRA)?
The closing price on Nov 16, 2026 was $22.50. Our estimate is $16.22, about 28% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Damora Therapeutics, Inc. right now?
The price sits above even our optimistic bull case ($20.27). The favourable scenario is already priced in. Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Damora Therapeutics, Inc.

How large is the market capitalisation of Damora Therapeutics, Inc. (DMRA)?
The market capitalisation of Damora Therapeutics, Inc. is $1.4B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Damora Therapeutics, Inc. (DMRA)?
Earnings per share at Damora Therapeutics, Inc. are $1.71 (price ÷ EPS = P/E 13.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Damora Therapeutics, Inc. (DMRA)?
The return on equity (ROE) of Damora Therapeutics, Inc. is −116% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Damora Therapeutics, Inc. (DMRA)?
On an EBIT basis the return on assets of Damora Therapeutics, Inc. is −80.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Damora Therapeutics, Inc. (DMRA) generate?
The free cash flow of Damora Therapeutics, Inc. is −$6.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Damora Therapeutics, Inc. (DMRA) hold?
Damora Therapeutics, Inc. holds more cash than debt, $258M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Damora Therapeutics, Inc. in the live analysis

One click puts Damora Therapeutics, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.